Clinical trials: Non-Cirrhotic
Cirrhosis
Ventriculo-arterial Coupling in Cirrhotics
Cirrhotic in intensive care unit have a very specific haemodynamic status. Cardiovascular abnormalities in advanced liver cirrhosis are characterized by a hyperdynamic circulation featuring increased heart rate and high cardiac…
- Trial name
- VACCI (NCT03948659)
- Testing
- Arterio ventricular coupling
- Where
- France
- Volunteers
- 13 people
- Sponsor
- Hospices Civils de Lyon
Portal Vein Thrombosis
Clinical Course of Cirrhotic Patients With Portal Vein Thrombosis Treated With TIPS
Portal vein thrombosis (PVT) is defined as an obstruction of the portal vein. The prevalence of PVT is 10-25% and incidence is about 16% in cirrhotic patients.
- Trial name
- NCT03031717
- Testing
- Transjugular intrahepatic portosystemic shunt
- Where
- Mexico
- Volunteers
- 15 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Liver Neoplasms, Liver Cirrhosis
Chemotherapy or Not, Following Complete Treatment of Hepatic Cancer in Cirrhotic Patients
Besides liver transplantation, the curative treatment of primary hepatic cancer with cirrhosis remains the surgical resection. Radiofrequency or cryotherapy currently allow local ablation of small cancer, with very good results.
- Conditions
- Liver Neoplasms, Liver Cirrhosis, Carcinoma, Hepatocellular, Recurrence
- Trial name
- GEMOXIAL (NCT00470340)
- Testing
- Oxaliplatin, gemcitabine, cisplatin, lipiodol
- Where
- France
- Volunteers
- 263 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cirrhosis, Liver, Portal Hypertension
Cirrhotic and Non-cirrhotic Patients With Clinically Significant Portal Hypertension
Alterations in conventional coagulation tests in patients with cirrhosis and/or portal hypertension do not reliably predict bleeding risk, as hemostatic balance is complex and often compensated.
- Conditions
- Cirrhosis, Liver, Portal Hypertension, Clinically Significant Portal Hypertension(CSPH), Gastroesophageal Varices
- Trial name
- PREDIBLEED (NCT07405749)
- Where
- Italy
- Volunteers
- 2,500 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NASH With Fibrosis, MASH With Fibrosis
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3).
- Trial name
- NCT06215716
- Testing
- Efruxifermin
- Where
- 359 sites in United States, Argentina and 16 more
- Volunteers
- 1,650 people
- Sponsor
- Akero Therapeutics, Inc
Hepatitis C, Chronic
Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107)
The purpose of this study is to estimate the difference in the efficacy between a 16-week treatment regimen of boceprevir (BOC) in combination with peg-intron alpha 2b (P) plus ribavirin (R) (BOC + PR) and a 28-week treatment…
- Trial name
- NCT01945294
- Testing
- Boceprevir, Peg-interferon alfa-2b, Ribavirin
- Volunteers
- 257 people
- Sponsor
- Merck Sharp & Dohme LLC
Liver Cirrhosis, Portal Hypertension
Freiburg TIPS Registry
Patients with clinically significant portal hypertension allocated to implantation of a transjugular intrahepatic portosystemic shunt (TIPS) at the Department of Medicine II of the University Medical Center Freiburg, Germany will…
- Conditions
- Liver Cirrhosis, Portal Hypertension, Non-Cirrhotic Portal Hypertension, Budd Chiari Syndrome
- Trial name
- FRETIR (NCT05782556)
- Testing
- Implantation of a transjugular intrahepatic portosystemic shunt (TIPS)
- Where
- Germany
- Volunteers
- 2,000 people
- Sponsor
- University Hospital Freiburg
Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection
A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)
The purpose of this study is to assess the efficacy and safety of ABT-493/ABT-530 in adults with chronic hepatitis C virus genotype 1-6 infection and human immunodeficiency virus-1 co-infection.
- Conditions
- Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection, Chronic Hepatitis C, Compensated Cirrhosis and Non-cirrhotics
- Trial name
- EXPEDITION-2 (NCT02738138)
- Testing
- ABT-493 coformulated with ABT-530
- Volunteers
- 153 people
- Sponsor
- AbbVie
Hepatitis C, Chronic
Eight Weeks of Elbasvir/Grazoprevir in the Treatment of HCV Genotype 4
To evaluate the safety and efficacy of a daily, fixed-dose, 8-week course combination of Elbasvir/Grazoprevir in treatment-naïve, non-cirrhotic patients who are mono-infected with hepatitis C, genotype 4.
- Trial name
- ELEGANT-4 (NCT03578640)
- Testing
- Elbasvir, Grazoprevir 50-100Mg Oral Tablet
- Where
- Saudi Arabia
- Volunteers
- 30 people
- Sponsor
- King Fahad Medical City
Liver Failure, Major Hepatectomy
Pneumatic Reversible Portal Vein Diameter Modulation After Major Hepatectomy
This ring aimed to preserve an intra-hepatic porto-caval gradient inferior to 5 mm Hg during and after major hepatectomy (48h) to protect the liver during the initial phases of liver regeneration.
- Trial name
- MODHEP1 (NCT02390713)
- Testing
- MID-AVR
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Chronic Hepatitis C Virus, Hepatitis C Virus
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection
The purpose of this phase 3, multicenter study is to evaluate the efficacy and safety of ABT-493/ABT-530 in Japanese adults with chronic Hepatitis C Virus (HCV)-infected, HCV direct-acting antiviral agent (DAA) treatment-naïve…
- Trial name
- CERTAIN-1 (NCT02707952)
- Testing
- ABT-493/ABT-530, OBV/PTV/r
- Volunteers
- 295 people
- Sponsor
- AbbVie
Cirrhosis
To Study and Compare the Clinical Course and Development of Organ Failure in Severe Acute Hepatitis Without Ascites, Non-cirrhotic and Cirrhotic Patients With Ascites [Acute on Chronic Liver Failure] and Acute Deterioration of Previously Decompensated Cirrhosis.
The study will be conducted on patients admitted to Department of Hepatology from MARCH 2015 to DECEMBER 2016 at ILBS, New Delhi.All patients presenting to ILBS fulfilling the inclusion criteria will be included in the study and…
- Trial name
- NCT02465619
- Where
- India
- Sponsor
- Institute of Liver and Biliary Sciences, India
Healthy Volunteers, Primary Sclerosing Cholangitis
A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)
The main aim of this study is to see if the drug TAK-781 is safe for healthy volunteers and for participants with PSC. The study will also look at how well participants can tolerate TAK-781.
- Trial name
- NCT07229911
- Testing
- TAK-781
- Where
- United States
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Takeda
Chronic Hepatitis C Virus (HCV) Infection
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection
The purpose of this study is to assess the efficacy and safety of 12 weeks of treatment with the ABT-493/ABT-530 combination regimen in adults with chronic HCV genotype 1 - 6 infection and chronic severe renal impairment.
- Trial name
- EXPEDITION-4 (NCT02651194)
- Testing
- ABT-493/ABT-530
- Volunteers
- 104 people
- Sponsor
- AbbVie
Hepatitis C, Hepatitis B
Neurocognitive Functioning in Patients With Hepatitis C Pre- and Post-Treatment With Antiviral Medication
The estimated global prevalence of hepatitis C (HCV) infection is approximately 3% (170 million individuals). In Canada there are an estimated 240,000 people infected with HCV.
- Trial name
- NCT00188201
- Where
- Canada
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Liver Cirrhosis
Intragastric Balloon in Compensated NASH(Non Alcoholic Steato Hepatitis) Cirrhotics
The study will be conducted in department of Hepatology at ILBS, the patients will be recruited from the OPD or IPD . The obese cirrhotic patients with NASH will be observed for standard of care and also patients who undergo IGB…
- Trial name
- NCT03753438
- Testing
- Intragstric Ballooning
- Where
- India
- Volunteers
- 56 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Hepatocellular Carcinoma
Risk Factors of Hepatocellular Carcinomas Developed on Non-fibrotic Liver: Case-control Study (NoFlic Study)
The main objective of this study is to identify direct carcinogenic factors in the absence of cirrhosis, and the carcinogenesis pathways involved on nonfibrotic liver (NfCHC).
- Trial name
- NoFlic (NCT03852238)
- Testing
- Blood test and self-administrated questionnaires
- Where
- 14 sites in France
- Volunteers
- 283 people
- Sponsor
- University Hospital, Bordeaux
Cirrhosis, Ascites
Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites
We wish to perform a multicenter, double-blind RCT with two parallel-group stratified on the center, comparing rifaximin to no rifaximin (placebo) for the primary prophylaxis of SBP in 'severe' cirrhotic patients with large…
- Conditions
- Cirrhosis, Ascites, Peritonitis
- Trial name
- ProPILARifax (NCT03069131)
- Testing
- Rifaximin
- Where
- 18 sites in France
- Volunteers
- 160 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Chronic Hepatitis C
Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV
This is an extension of ongoing study SCI-SCV-HCV-P2-001 in which subjects will be invited to participate in this extension study if they complete treatment in study SCI-SCV-HCV-P2-001 and are eligible for retreatment with…
- Trial name
- NCT01310205
- Testing
- SCV-07
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- SciClone Pharmaceuticals
Portal Hypertension, Non-Cirrhotic Portal Hypertension
Hepatic Venous Pressure Gradient and Elastography in Porto-sinusoidal Vascular Disorder
Porto-sinusoidal vascular disorder (PSVD) is considered a rare cause of portal hypertension (PH), resulting from specific histological alterations that essentially affect the small portal branches and sinusoids, in the absence of…
- Conditions
- Portal Hypertension, Non-Cirrhotic Portal Hypertension, Non-Cirrhotic Portal Fibrosis, Regenerative Nodular Hyperplasia
- Trial name
- NCT05719857
- Testing
- Hepatic vein pressure gradient measurement, Ultrasound-guided percutaneous liver biopsy, Multiparametric Abdominal Magnetic Resonance with Elastography
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Universidade Federal do Rio de Janeiro